BSL2v1c2 polypeptides

Details BSL2v1c2 polypeptides BSL2v1c2 polypeptides

2008-02-07

2010-10-05

Ouspenski, Ilia (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Reexamination Certificate

active

07807786

ABSTRACT:
The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.

REFERENCES:
patent: 6429303 (2002-08-01), Green et al.
patent: 6630575 (2003-10-01), Coyle et al.
patent: 6635750 (2003-10-01), Coyle et al.
patent: 2002/0106730 (2002-08-01), Coyle et al.
patent: 2004/0077043 (2004-04-01), Watarai et al.
patent: 2004/0137577 (2004-07-01), Coyle et al.
patent: 2004/0162236 (2004-08-01), Alsobrook et al.
patent: 2004/0236088 (2004-11-01), Heuer et al.
patent: 2006/0154313 (2006-07-01), Anderson et al.
patent: 1067182 (2001-01-01), None
patent: 1074617 (2001-02-01), None
patent: 1130094 (2001-09-01), None
patent: WO9819706 (1998-05-01), None
patent: WO98/58965 (1998-12-01), None
patent: WO9946281 (1999-03-01), None
patent: WO 99/46281 (1999-09-01), None
patent: WO9947558 (1999-09-01), None
patent: EP1074617 (2000-07-01), None
patent: WO 00/55375 (2000-09-01), None
patent: WO0053756 (2000-09-01), None
patent: WO 00/61612 (2000-10-01), None
patent: WO 00/68266 (2000-11-01), None
patent: WO0068266 (2000-11-01), None
patent: WO 01/18021 (2001-03-01), None
patent: WO 01/18022 (2001-03-01), None
patent: WO 01/18204 (2001-03-01), None
patent: WO0114556 (2001-03-01), None
patent: WO0114566 (2001-03-01), None
patent: WO0114577 (2001-03-01), None
patent: WO0121631 (2001-03-01), None
patent: WO0134629 (2001-05-01), None
patent: WO0134768 (2001-05-01), None
patent: WO0139722 (2001-06-01), None
patent: WO0168848 (2001-09-01), None
patent: WO0183750 (2001-11-01), None
patent: WO0200692 (2002-01-01), None
patent: WO0200730 (2002-01-01), None
patent: WO0208279 (2002-01-01), None
patent: WO0210187 (2002-02-01), None
patent: WO0222683 (2002-03-01), None
patent: WO02097046 (2002-12-01), None
patent: WO03/014293 (2003-02-01), None
patent: WO03085124 (2003-10-01), None
patent: WO2004093894 (2004-11-01), None
U.S. Appl. No. 60/196,967, filed Apr. 13, 2000, Anderson Dirk.
Kahan, Cur. Opin. Immunol., 1992, 4(5): 553-560.
Blazer, et al., J. Immunol., 1996, 157(8): 3250-3259.
Perrin, et al., J. Neuroimmunol, 1996, 65: 31-39.
Castriconi, et al., “Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis”, PNAS, vol. 101(34), pp. 12640-12645 (2004).
Collins, et al., “The B7 family of immune-regulatory ligands”, Genome Biol., vol. 6, pp. 223.1-223.7 (2005).
Dong, et al., “Immune Regulation by Novel Costimulatory Molecules”, Immunologic Res., vol. 28(1), pp. 39-48 (2003).
Ferlazzo, et al., “T lymphocytes express B7 family molecules following interaction with dendritic cells and acquire bystander costimulatory properties”, Eur. J. Immunol., vol. 32, pp. 3092-3101 (2002).
Greenwald, et al., “The B7 Family Revisited”, Annu. Rev. Immunol., vol. 23, pp. 515-548 (2005).
Kim, et al., “Constitutive and Inducible Expression of B7 Family of Ligands by Human Airway Epithelial Cells”, Am. J. Respir. Cell Mol. Biol., vol. 33, pp. 280-289 (2005).
Lane, et al., “mRNA for Genes Associated with Antigen Presentation are Expressed by Human Middle Meatal Epithelial Cells in Culture”, The Laryngoscope, vol. 114, pp. 1827-1832 (2004).
Ling, et al., “Duplication of primate and rodent B7-H3 immunoglobulin V- and C- like domains: divergent history of functional redundancy and exon loss”, Genomics, vol. 82, pp. 365-377 (2003).
Loke, et al., Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells, Arthritis Res. Therapy, vol. 6(5), pp. 208-214 (2004).
Luo, et al., “B7-H3 Enhances Tumor Immunity In Vivo by Costimulating Rapid Clonal Expansion of Antigen-Specific CD8+Cytolytic T Cells”, J. Immunol., vol. 173, pp. 5445-5450 (2004).
Petroff, et al., “The Immunomodulatory Proteins B7-DC, B7-H2, and B7-H3 Are Differentially Expressed across Gestation in the Human Placenta”, Amer. J. Pathology, vol. 167(2), pp. 465-473 (2005).
Prasad, et al., “Murine B7-H3 Is a Negative Regulator of T Cells”, J. Immunol., vol. 173, pp. 2500-2506 (2004).
Saatian, et al., “Expression of genes for B7-H3 and other T cell ligands by nasal epithelial cells during differentiation and activation”, Am. J. Physiol. Lung Cell Mol. Physiol., vol. 287, pp. L127-L225 (2004).
Steinberger, et al., “Molecular Characterization of Human 4Ig-B7-H3, a Member of the B7 Family with Four Ig-Like Domains”, J. Immunol., vol. 172, pp. 2352-2359 (2004).
Suh, et al., The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses, Nature Immunol., vol. 4(9), pp. 899-906 (2003).
Suh, et al., “The immune regulatory protein B7-H3 promotes osteoblast differentiation and bone mineralization”, PNAS, vol. 101(35), pp. 12969-12973 (2004).
Sun, et al., “Mouse B7-H3 induces antitumor immunity”, Gene Therapy, vol. 10, pp. 1728-1734 (2003).
Thomas, et al., “A Cell-Based Artificial Antigen-Presenting Cell Coated with Anti-CD3 and CD28 Antibodies Enables Rapid Expansion and Long-Term Growth of CD4 T Lymphocytes”, Clinical Immunol., vol. 105(3), pp. 259-272 (2002).
Wang, et al., “Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses”, Microbes Infection, vol. 6, pp. 759-766 (2004).
Wang, et al., “B7-H3 promotes acute and chronic allograft rejection”, Eur. J. Immunol., vol. 35, pp. 428-438 (2005).
Zhang, et al., “Human Recombinant B7-H3 Expressed inE. coliEnhances T Lymphocyte Proliferation and IL-10 Secretion in Vitro”, Acta Biochimica Biophysica Sinica, vol. 36(6), pp. 430-436 (2004).
Ellison, et al., “The nucleotide sequence of a human immunoglobulin Cγ1gene”, Nucleic Acids Res., vol. 10(13), pp. 4071-4079 (1982).
NCBI Entrez Accession No. AAK15370 (gi:13183883), Latchman, et al., Apr. 8, 2002.
NCBI Entrez Accession No. AAK31105 (gi:13569410), Tseng, et al., Apr. 10, 2001.
NCBI Entrez Accession No. AAK15438(gi:13194193), Chapoval, et al., Mar. 3, 2001.
NCBI Entrez Accession No. AK001872 (gi:7023409), Ota, et al., Sep. 12, 2006.
NCBI Entrez Accession No. XP—039673 (gi:14741814), NCBI Annotation Project, Oct. 16, 2001.
Finck, et al., “Treatment of Murine Lupus with CTLA4Ig”, Science vol. 265, po. 1225-1227 (1994).
Kremer, et al., “Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig”, N Engl. J. Med., vol. 349(20), pp. 1907-1915 (2003).
Tan, et al., “Induction of Alloantigen-specific Hyporesponsiveness in Human T Lymphocytes by Blocking Interaction of CD28 with Its Natural Ligand B7/BB1”, J. Exp. Med., vol. 177, pp. 165-173 (1993).
Webb, et al., “Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2”, Eur. J. Immunol., vol. 26, pp. 2320-2328 (1996).
NCBI Entrez Accession No. gi|7023409, T. Isogai et al., Feb. 22, 2000.
NCBI Entrez Accession No. gi|13376850, Y. Latchman et al., Mar. 18, 2001.
NCBI Entrez Accession No. gi|13376852, A.I. Chapoval et al., Mar. 18, 2001.
NCBI Entrez Accession No. gi|13640665, NCBI Annotation Project, Oct. 16, 2001.
NCBI Entrez Accessio

Affiliated with

Also associated with

Rating

BSL2v1c2 polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with BSL2v1c2 polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and BSL2v1c2 polypeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4191089